This can also be done through blocking rhodopsin regeneration and binding of 11CR (Radu et al., 2003; Sieving et al., 2001), reducing the light-dependent accumulation of atRAL condensation products such as diretinoid-pyridinium-ethanolamine (A2E), which contributes to lipofuscin deposits in the retinal pigment epithelium associated with human retinal diseases (Maeda et al., 2009; Chen et al., 2012b; Radu et al., 2003; Sparrow, 2003). The gene discussed is RHO; the disease is Abnormal retinal morphology.